Monashee Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Monashee Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	+75,000	New	+$1.36M	2.45%	18
2024 Q4	–	Sell	-50,000	Closed	-$2.52M	–	74
2024 Q3	$2.52M	Hold	50,000	–	–	0.27%	54
2024 Q2	$2.2M	Sell	50,000 -65,000	-57%	-$2.75M	0.28%	39
2024 Q1	$5.78M	Buy	+115,000	New	+$6.24M	0.68%	23
2023 Q4	–	Sell	-50,000	Closed	-$2.85M	–	71
2023 Q3	$2.85M	Hold	50,000	–	–	1.19%	32
2023 Q2	$2.55M	Buy	+50,000	New	+$1.35M	0.61%	32
2022 Q4	–	Sell	-191,945	Closed	-$1.49M	–	57
2022 Q3	$1.49M	Sell	191,945 -8,055	-4%	-$56.9K	0.55%	30
2022 Q2	$1.05M	Buy	+200,000	New	+$1.26M	0.38%	19

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Monashee Investment Management's MLTX Position: Q2 2026 in Review

Monashee Investment Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 75,000 shares worth $1.46M. The stake represents 2.45% of the portfolio and ranks #18 among its holdings. This is a return to the name: Monashee Investment Management previously reported a position in MLTX as recently as Q3 2024.

Monashee Investment Management first reported a position in MLTX in Q2 2022 and has held it in 8 quarters since. The position peaked at $5.78M in Q1 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Monashee Investment Management held 75,000 shares of MoonLake Immunotherapeutics worth $1.46M as of Q2 2026.
MoonLake Immunotherapeutics was a new Monashee Investment Management position in Q2 2026.
MoonLake Immunotherapeutics made up 2.45% of Monashee Investment Management's portfolio in Q2 2026, its #18 holding.
Monashee Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 8 quarters since.
Monashee Investment Management's MoonLake Immunotherapeutics position peaked at $5.78M in Q1 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Monashee Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.